ID   U2OS-GFP-STAT1/CSF-1R
AC   CVCL_D7E2
RX   Patent=US9683988;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.4688.
CC   Population: Caucasian.
CC   Characteristics: Expresses both GFP-STAT1 and CSF1R (Patent=US9683988).
CC   Sequence variation: Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=FPbase; R9NL8; eGFP (Note=Enhanced GFP).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2433; CSF1R.
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:11362; STAT1.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Klebsiella pneumoniae transposon Tn5 neo.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P13249; Streptomyces alboniger pac (PuroR).
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D7E1 ! U2OS-GFP-STAT1
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 14-08-25; Version: 4
//
RX   Patent=US9683988;
RA   Wang, Li-Li
RA   Yang, Sheng-Qian
RA   Long, Long
RA   Xiao, Jun-Hai
RA   Li, Song
RT   "Cell model and method for screening c-Fms kinase inhibitors.";
RL   Patent number US9683988, 20-Jun-2017.
//